The Free Fatty Acid Receptor 1 pipeline drugs market research report outlays comprehensive information on the Free Fatty Acid Receptor 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Free Fatty Acid Receptor 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Metabolic Disorders, Undisclosed, Central Nervous System, and Gastrointestinal which include the indications Type 2 Diabetes, Diabetes, Unspecified, Diabetic Neuropathy, Metabolic Dysfunction-Associated Steatohepatitis (MASH), and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). It also reviews key players involved in Free Fatty Acid Receptor 1 targeted therapeutics development with respective active and dormant or discontinued products.
The Free Fatty Acid Receptor 1 pipeline targets constitutes close to 16 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 3, 2, 1, 5, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 4 molecule.
Free Fatty Acid Receptor 1 overview
Free fatty acid receptor 1 (FFA1), also known as GPR40, is a class A G-protein coupled receptor that is encoded by the FFAR1 gene. It is strongly expressed in the pancreatic islet cells and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis.
For a complete picture of Free Fatty Acid Receptor 1’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
